IN2013MN01547A - - Google Patents
Download PDFInfo
- Publication number
- IN2013MN01547A IN2013MN01547A IN1547MUN2013A IN2013MN01547A IN 2013MN01547 A IN2013MN01547 A IN 2013MN01547A IN 1547MUN2013 A IN1547MUN2013 A IN 1547MUN2013A IN 2013MN01547 A IN2013MN01547 A IN 2013MN01547A
- Authority
- IN
- India
- Prior art keywords
- wounds
- treating
- molecular target
- ptprk
- protein
- Prior art date
Links
- 206010052428 Wound Diseases 0.000 abstract 4
- 208000027418 Wounds and injury Diseases 0.000 abstract 4
- 101000591201 Homo sapiens Receptor-type tyrosine-protein phosphatase kappa Proteins 0.000 abstract 2
- 102100034089 Receptor-type tyrosine-protein phosphatase kappa Human genes 0.000 abstract 2
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/29—Antimony or bismuth compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/121—Hammerhead
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1103898.1A GB201103898D0 (en) | 2011-03-08 | 2011-03-08 | Molecular targets for healing or treating wounds |
| PCT/GB2012/050362 WO2012120269A1 (fr) | 2011-03-08 | 2012-02-17 | Cibles moléculaires pour la guérison ou le traitement des blessures |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2013MN01547A true IN2013MN01547A (fr) | 2015-06-12 |
Family
ID=43923365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1547MUN2013 IN2013MN01547A (fr) | 2011-03-08 | 2012-02-17 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20140213629A1 (fr) |
| EP (1) | EP2683823B1 (fr) |
| JP (1) | JP5986116B2 (fr) |
| CN (1) | CN103443276B (fr) |
| AU (1) | AU2012226593B2 (fr) |
| CA (1) | CA2829010A1 (fr) |
| GB (2) | GB201103898D0 (fr) |
| HK (1) | HK1192904A1 (fr) |
| IN (1) | IN2013MN01547A (fr) |
| WO (1) | WO2012120269A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014183062A1 (fr) * | 2013-05-10 | 2014-11-13 | La Jolla Institute For Allergy And Immunology | Traitements de maladies autoimmunes |
| WO2015019125A1 (fr) * | 2013-08-05 | 2015-02-12 | Societe De Developpement Et De Recherche Industrielle | Cibles moléculaires destinées au traitement des blessures, en particulier des blessures chroniques |
| WO2020176790A1 (fr) * | 2019-02-27 | 2020-09-03 | Fred Hutchinson Cancer Research Center | Compositions d'hydrogel et méthodes de traitement de cancers |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6204000B1 (en) | 1995-04-28 | 2001-03-20 | The United States Of America As Represented By The Department Of Health And Human Services | Diagnostic methods and gene therapy using reagents derived from the human metastasis suppressor gene KAI1 |
| KR100366439B1 (ko) * | 2000-02-21 | 2003-01-09 | 주식회사 대웅 | 상피세포 성장인자를 유효성분으로 하는 안정한 약제학적조성물 |
| US20050215629A1 (en) | 2001-09-07 | 2005-09-29 | Taolin Yi | PTPase inhibitors and methods of using the same |
| AU2002339904A1 (en) * | 2001-09-07 | 2003-09-09 | The Cleveland Clinic Foundation | Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases |
| US7844214B2 (en) | 2002-03-02 | 2010-11-30 | Nokia Corporation | System and method for broadband digital broadcasting |
| EP1482966B1 (fr) * | 2002-03-12 | 2014-05-14 | Bio-Click Technologies Ltd | Methode et composition de traitement de lesions cutanees avec un facteur de croissance epidermique |
| US20040009597A1 (en) * | 2002-07-03 | 2004-01-15 | Isis Pharmaceuticals Inc. | Antisense modulation of PTPRK expression |
| CA2506619A1 (fr) | 2002-11-18 | 2004-08-19 | Thomas W. Hodge | Lignees cellulaires et sequences d'acides nucleiques hotes associees a des maladies infectieuses |
| JP2006517092A (ja) | 2002-11-27 | 2006-07-20 | アルテシアン セラピューティック，インコーポレイティド | 心不全遺伝子の決定及び治療薬スクリーニング |
| GB2396106B (en) * | 2002-12-12 | 2006-11-15 | Johnson & Johnson Medical Ltd | Wound dressings comprising enzyme inhibitors |
| EP1670946B1 (fr) | 2003-09-19 | 2012-11-07 | bioTheranostics, Inc. | Prevision du resultat d'un traitement contre le cancer du sein |
| US20050170445A1 (en) | 2004-01-07 | 2005-08-04 | Duke University | Methods of establishing profiles for use in evaluating wound healing and biocompatibility of implant materials and microarrays useful therefor |
| WO2006108225A1 (fr) | 2005-04-11 | 2006-10-19 | Garvan Institute Of Medical Research | Procede de criblage pour des composes qui modulent la proliferation cellulaire |
| US20090203006A1 (en) | 2006-05-01 | 2009-08-13 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Biological markers of chronic wound tissue and methods of using for criteria in surgical debridement |
| WO2008005276A2 (fr) * | 2006-06-30 | 2008-01-10 | Directcontact Llc | Dispositif médical/système destiné à administrer un médicament pour soigner des blessures et prévenir une inflammation ou une maladie |
| CA2707900A1 (fr) | 2007-12-07 | 2009-06-18 | Oregon Health & Science University | Procedes permettant de determiner si un sujet reagira a un inhibiteur bcr-abl |
| US20110305703A1 (en) | 2008-12-08 | 2011-12-15 | Vegenics Pty Limited | Isolated vegf-c and vegf-d peptides and uses thereof |
| WO2010085606A1 (fr) | 2009-01-22 | 2010-07-29 | Case Western Reserve University | Biomarqueurs protéiniques et cibles thérapeutiques pour l'arthrose |
| CN101671729B (zh) | 2009-09-07 | 2012-09-05 | 张力建 | 用于肺癌治疗方案选择和/或预后评估的基因群、基因芯片和检测试剂盒 |
| GB0916124D0 (en) | 2009-09-15 | 2009-10-28 | Univ Cardiff | Method and kit for the classification and prognosis of wounds |
-
2011
- 2011-03-08 GB GBGB1103898.1A patent/GB201103898D0/en not_active Ceased
-
2012
- 2012-02-17 JP JP2013557169A patent/JP5986116B2/ja active Active
- 2012-02-17 GB GB1314859.8A patent/GB2502017A/en not_active Withdrawn
- 2012-02-17 IN IN1547MUN2013 patent/IN2013MN01547A/en unknown
- 2012-02-17 CN CN201280010963.9A patent/CN103443276B/zh active Active
- 2012-02-17 AU AU2012226593A patent/AU2012226593B2/en active Active
- 2012-02-17 WO PCT/GB2012/050362 patent/WO2012120269A1/fr active Application Filing
- 2012-02-17 EP EP12708372.3A patent/EP2683823B1/fr active Active
- 2012-02-17 US US14/000,532 patent/US20140213629A1/en not_active Abandoned
- 2012-02-17 CA CA2829010A patent/CA2829010A1/fr not_active Abandoned
-
2014
- 2014-06-25 HK HK14106417.6A patent/HK1192904A1/zh unknown
-
2016
- 2016-05-09 US US15/149,638 patent/US9782381B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014511392A (ja) | 2014-05-15 |
| CN103443276A (zh) | 2013-12-11 |
| EP2683823B1 (fr) | 2016-07-20 |
| US20160331716A1 (en) | 2016-11-17 |
| US20140213629A1 (en) | 2014-07-31 |
| GB201103898D0 (en) | 2011-04-20 |
| HK1192904A1 (zh) | 2014-09-05 |
| CA2829010A1 (fr) | 2012-09-13 |
| WO2012120269A1 (fr) | 2012-09-13 |
| JP5986116B2 (ja) | 2016-09-06 |
| US9782381B2 (en) | 2017-10-10 |
| AU2012226593B2 (en) | 2016-06-02 |
| EP2683823A1 (fr) | 2014-01-15 |
| GB201314859D0 (en) | 2013-10-02 |
| CN103443276B (zh) | 2016-09-28 |
| GB2502017A (en) | 2013-11-13 |
| AU2012226593A1 (en) | 2013-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1117655T1 (el) | Παραγοντες οι οποιοι επαγουν αποπτωση για την αντιμετωπιση καρκινου και ανοσολογικων και αυτοανοσων νοσηματων | |
| AU2011328009A8 (en) | Compounds and methods for treating pain | |
| CY1116728T1 (el) | Παραγοντες οι οποιοι επαγουν αποπτωση για την αντιμετωπιση καρκινου και ανοσολογικων και αυτοανοσων νοσηματων | |
| BR112013006673A2 (pt) | produtos terapêuticos para câncer de mama | |
| EP3195868A3 (fr) | Utilisation thérapeutique d'un agoniste de tlr, et polythérapie | |
| MX2012013731A (es) | Vacunas que comprenden colesterol y cpg como moleculas portadoras-adyuvantes unicas. | |
| MX366130B (es) | Inhibidores bivalentes de las proteinas iap y métodos terapéuticos que usan los mismos. | |
| EP3747457A3 (fr) | Protéine du facteur 1, protéine du facteur 2 et leurs inhibiteurs destinés à être utilisés dans le traitement ou la prévention de maladies | |
| WO2015054619A3 (fr) | Utilisation d'un inhibiteur de pcsk9 pour traiter l'hyperlipidémie | |
| WO2013169864A3 (fr) | Tétrahydro[1,8]naphtyridine-sulfonamide et composés apparentés pour utilisation en tant qu'agonistes de rorγ et dans le traitement d'une maladie | |
| BR112015000776A2 (pt) | Agentes de ligação à rspo3 e usos dos mesmos | |
| BR112013020159A2 (pt) | método para inibir células tumorais de hamartoma | |
| MA40057A (fr) | Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants | |
| MX2019007057A (es) | Composiciones de adenovirus. | |
| EP3818991A3 (fr) | Compositions et procédés de traitement de maladies | |
| WO2016090024A3 (fr) | Polythérapie pour le traitement du cancer | |
| MX2013008530A (es) | Peptidos a base de lactoferrina humana que tienen actividad antiinflamatoria. | |
| MX2014001393A (es) | 3-(bifenil-3-il)-4-hidroxi-8-metoxi-1-azaespiro[4.5]dec-3-en-2-on as sustituidas. | |
| MX2015007719A (es) | Terapia dirigida del receptor del factor de crecimiento epidermico (egfr) de trastornos neurologicos y dolor. | |
| MY173174A (en) | Short bio-active peptides for promoting wound healing | |
| IN2013MN01547A (fr) | ||
| MX2015005733A (es) | Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad. | |
| MX2013002539A (es) | Sobrenadante condicionado por leucocitos activados y usos para la cicatrizacion de heridas. | |
| MX2016004212A (es) | Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas. | |
| TN2013000336A1 (en) | 5s,8s)-3-(4'-chlor-3'-fluoro-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for therapy. |